ZVSA — Zyversa Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.21m
- $0.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.26 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -97.53% | ||
| Return on Equity | -96.1% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate, Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis. VAR 200’s active ingredient, 2-hydroxypropyl-beta-cyclodextrin, comprises seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 17th, 2021
- Public Since
- December 21st, 2021
- No. of Shareholders
- 90
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,619,456
- Address
- 2200 N. Commerce Parkway, Suite 208, WESTON, 33326
- Web
- https://www.zyversa.com/
- Phone
- +1 7542311688
- Auditors
- Marcum LLP
Upcoming Events for ZVSA
Zyversa Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Zyversa Therapeutics Inc Earnings Release
Similar to ZVSA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Zyversa Therapeutics share price?
As of Today at 24:18 UTC, shares in Zyversa Therapeutics are trading at $0.61. This share price information is delayed by 15 minutes.
How has the Zyversa Therapeutics share price performed this year?
Shares in Zyversa Therapeutics last closed at $0.61 and the price had moved by -89.37% over the past 365 days. In terms of relative price strength the Zyversa Therapeutics share price has underperformed the S&P500 Index by -90.42% over the past year.
What are the analyst and broker recommendations for Zyversa Therapeutics?
The overall consensus recommendation for Zyversa Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Zyversa Therapeutics dividend yield?
Zyversa Therapeutics does not currently pay a dividend.
Does Zyversa Therapeutics pay a dividend?
Zyversa Therapeutics does not currently pay a dividend.
When does Zyversa Therapeutics next pay dividends?
Zyversa Therapeutics does not currently pay a dividend.
How do I buy Zyversa Therapeutics shares?
To buy shares in Zyversa Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zyversa Therapeutics?
As of the previous close price of $0.61, shares in Zyversa Therapeutics had a market capitalisation of $2.21m.
Where are Zyversa Therapeutics shares listed?
Here are the trading details for Zyversa Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ZVSA
What kind of share is Zyversa Therapeutics?
Based on an overall assessment of its quality, value and momentum Zyversa Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zyversa Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Zyversa Therapeutics is $120.00. That is 19572.13% above the last closing price of $0.61.
Analysts covering Zyversa Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.23 for the next financial year.
Find out moreWhat is the trend in the Zyversa Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zyversa Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -67.92%.
As of the last closing price of $0.61, shares in Zyversa Therapeutics were trading -64.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zyversa Therapeutics PE Ratio?
The Zyversa Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zyversa Therapeutics?
We do not have data on Zyversa Therapeutics' directors